Balaji Amines Ltd

Balaji Amines Earnings Call Transcript: Key Takeaways

Q2 FY27 revenue rose 36% YoY to ₹472 Cr and PAT rose 82%, but volumes fell 6% YoY and EBITDA dropped QoQ from ₹121 Cr to ₹106 Cr.

Balaji Amines Investor Presentation: Key Takeaways

Q2 FY27 consolidated revenue ₹472 Cr (+36% YoY), EBITDA ₹106 Cr (22% margin), PAT ₹67 Cr (+82%). H1 consolidated PAT ₹146 Cr. Standalone debt-free; DME, ACN commercialised; NMM and BSCL expansions ongoing.

Balaji Amines Legal & Regulatory

Balaji Amines received summons from Ahmedabad City Civil Court over alleged Drugs and Cosmetics Act violations. The company states no material financial or operational impact.

Balaji Amines Results Update

Balaji Amines reported Q2 FY27 consolidated revenue of ₹472 Cr and net profit of ₹67 Cr. Its expanded ACN facility reached 1,440 TPM capacity with commercial production commenced.

Acetonitrile (ACN) manufacturing capacity

1440 TPM

Balaji Amines Q2 FY27 Results: Net Profit ₹67.5 Cr, Up 81.9% YoY

Balaji Amines Ltd reported revenue from operations of ₹467.6 Cr (+37.3% YoY) and net profit of ₹67.5 Cr (+81.9% YoY) for Q2 FY27.

Key figure

Net profit ₹67.5 Cr · +81.9% YoY

Balaji Amines Board Meeting Date

Balaji Amines scheduled a board meeting on 2 November 2026 for September 2026 quarter and half-year results. Trading window reopens 48 hours after results.

Balaji Amines Other Announcement

The company filed its quarterly shareholding pattern under Regulation 31(1)(b) of the SEBI LODR Regulations for the period ended September 30, 2026.